Starna Therapeutics (Suzhou) Co Ltd

11/19/2026 | Press release | Distributed by Public on 11/19/2026 01:49

Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases

NEW YORK, [2026/11/18] - Pfizer Inc. (NYSE: PFE) today announced that it entered into an exclusive license agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases. Pfizer also receives rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in Greater China.

"In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today's options fall short. Pfizer has significant capabilities to develop and manufacture RNA-based medicines globally, and Starna's in vivo CAR-T platform and programs give us a powerful way to pursue these approaches."

- Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer

"Our vision at Starna is to unlock the potential of RNA medicines to transform patient care. We believe our proprietary targeted LNP delivery platform and RNA technology provide a strong foundation for advancing in vivo CAR-T therapies. We are excited to join forces with Pfizer, a global leader in drug development, to bring transformative therapies to patients worldwide."

- Rongkuan Hu, Ph,D,, Chief Executive Officer, Starna Therapeutics

Deal Terms and Financial Details

  • Starna will receive an upfront payment of $330 million.
  • Starna is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus tiered royalties on net sales of approved products.
  • Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in the United States.
  • Pfizer will have sole and exclusive control over commercialization outside of Greater China for all products
  • Pfizer holds options to expand its territory to include Greater China.

Advancing Promising Science for Patients


Today's agreement broadens Pfizer's Inflammation & Immunology pipeline and enables Pfizer to deploy its extensive scientific expertise in RNA delivery and specialization in immunology research, clinical development and commercialization to a promising, next-generation approach in cell therapy. Starna's innovative platform provides future opportunities to design potentially transformative autoimmune and cancer treatments.
For more information on Pfizer's Commitment to Immunology and Inflammation, please visit: Inflammation & Immunology | Pfizer.

About Pfizer: Breakthroughs That Change Patients' Lives


At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.comand follow us on X at @Pfizerand @Pfizer News,LinkedIn,YouTubeand like us on Facebook at Facebook.com/Pfizer.
Starna Therapeutics (Suzhou) Co Ltd published this content on November 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2026 at 07:50 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]